Incyte (INCY) is a publicly traded Healthcare sector company. As of May 20, 2026, INCY trades at $97.40 with a market cap of $19.02B and a P/E ratio of 36.15. INCY moved +1.56% today. Year to date, INCY is -5.74%; over the trailing twelve months it is +49.82%. Its 52-week range spans $53.56 to $112.29. Analyst consensus is buy with an average price target of $109.13. Rallies surfaces INCY's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Incyte to Present 20+ Abstracts Highlighting Hematology Pipeline at EHA 2026 Congress: Incyte secured acceptance of over 20 research abstracts for presentation at the European Hematology Association’s 2026 Congress, showcasing clinical and translational studies across its hematology pipeline. These submissions highlight data on multiple investigational candidates and could bolster perceptions of the company’s hematology portfolio strength.
| Metric | Value |
|---|---|
| Price | $97.40 |
| Market Cap | $19.02B |
| P/E Ratio | 36.15 |
| EPS | $2.67 |
| Dividend Yield | 0.00% |
| 52-Week High | $112.29 |
| 52-Week Low | $53.56 |
| Volume | 704.20K |
| Avg Volume | 0 |
| Revenue (TTM) | $3.70B |
| Net Income | $597.60M |
| Gross Margin | 93.10% |
17 analysts cover INCY: 0 strong buy, 8 buy, 8 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $109.13.